BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President [Yahoo! Finance]
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Yahoo! Finance
Additionally, BlossomHill appoints Ashley Preston, Ph.D., to Senior Vice President and Head of Regulatory Affairs and Quality Assurance SAN DIEGO, January 06, 2025 BUSINESS WIRE BlossomHill Therapeutics, Inc. , a clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the appointment of Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President. Dr. Oxnard is a globally recognized clinical and translational cancer investigator who spent nearly 10 years on faculty at the Dana-Farber Cancer Institute and Harvard Medical School. His research catalyzed many of the early clinical insights into sensitivity and resistance to EGFR inhibitors in advanced lung cancer, including the first description of the EGFR C797S resistance mutation, reported in Nature Medicine in 2015 "Since its founding in 2020, BlossomHill Therapeutics has established a robust and high-quality p
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
SYRS
Earnings
- 10/31/24 - Beat
SYRS
Analyst Actions
- 11/1/24 - HC Wainwright
SYRS
Sec Filings
- 12/30/24 - Form 144
- 12/27/24 - Form 144
- 12/13/24 - Form 144
- SYRS's page on the SEC website